NR4A2
MOLECULAR TARGETnuclear receptor subfamily 4 group A member 2
NR4A2 (nuclear receptor subfamily 4 group A member 2) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting NR4A2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | amodiaquine | 3.74 | 41 |
| 2 | celastrol | 3.22 | 24 |
| 3 | vidofludimus | 2.48 | 11 |
| 4 | tecastemizole | 2.30 | 9 |
| 5 | desmetheylastemizole | 2.08 | 7 |
| 6 | Alprostadil | 1.95 | 6 |
| 7 | prostaglandin a1 | 1.95 | 6 |
| 8 | parecoxib | 1.95 | 6 |
| 9 | Camptothecin | 1.79 | 5 |
| 10 | Progesterone | 1.10 | 2 |
| 11 | Simvastatin | 0.69 | 1 |
| 12 | Aldosterone | 0.69 | 1 |
| 13 | Triiodothyronine | 0.69 | 1 |
About NR4A2 as a Drug Target
NR4A2 (nuclear receptor subfamily 4 group A member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented NR4A2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
NR4A2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.